Press Room

AAPS 2015

Start
Sunday, October 25, 2015 - 00:00
End
Thursday, October 29, 2015 - 23:00
Location: Orlando, USA
Booth Number: 1845

HOVIONE'S PRESENTATION

Screening Methodologies for the Development of Spray-Dried Amorphous Solid Dispersions
Speaker: Marcio Temtem (Oral Drug Forms Group Leader)
Date: Tuesday, October 27, 2015
Time: 10:00 AM – 12:00 PM, OCCC - Room W310
This presentation will take place during the Roundtable Session "What a Guess! - How to Predict Which Polymer is the One for My Amorphous Solids Dispersion"

Expanding in the Right Direction
Speaker: Antonio Dinis (Director, Marketing & Communication)
Date: Tuesday, October 27 
Time: 10:25 AM - 10:40 AM, OCCC - End of 200 Aisle
Having Hovione’s expansion plans as a starting point we will explore how why capacity alone is not what make the company the leader in pharmaceutical spray drying. Development by Design cases studies will be presented to illustrate how Hovione is making strides to the third evolutionary stage of the industry.

 

Poster Session at AAPS:  

Evaporation of binary mixtures and shell formation in spray dried droplets
Pedro Valente

A Direct Approach for Spray Drying Process Development: From Laboratory to Commercial Scale
Rui Ferreira

Benchmarking the Bioperformance of Amorphous Solid Dispersions Produced by Spray Drying and a Solvent Controlled Precipitation Process
Iris Duarte

Predicting the performance of amorphous solid dispersions based on molecular descriptors and statistical analysis
Iris Duarte

Production of Co-crystals: Microfluidization vs High Shear Mixing Assisted Process
Tiago Profirio

Achieving High Efficiency Taste Masking with Particle Engineering
Inês Matos

Loss of Compactability in Roller Compaction—Influencing Parameters and Analytical Characterization
João Henriques

Analytical Qbd Model: a new stepwise methodology for analytical chemistry
Lúcia Volta e Sousa1,2, António Ramos1, Rui Loureiro1, José C. Menezes2
1 Hovione Farmaciência S.A.
2 Institute for Biotechnology and Biosciences, Instituto Superior Técnico, Universidade de Lisboa

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026